Sporotrichosis

Sporotrichosis is a fungal infection caused by dimorphic fungi of the Sporothrix species complex, most commonly Sporothrix schenckii and Sporothrix brasiliensis. This condition primarily affects the skin, subcutaneous tissues, and lymphatic system, though disseminated infections involving internal organs can occur in immunocompromised individuals. Often called rose gardener's disease in humans due to its association with thorn pricks and plant material exposure, sporotrichosis in dogs typically results from contaminated soil, vegetation, or organic matter entering through skin wounds. The condition has global distribution but is most prevalent in tropical and subtropical regions with warm, humid climates.

The Sporothrix organism exists in two forms depending on environmental conditions. In the environment, particularly in soil, decaying vegetation, and plant matter including sphagnum moss and rose thorns, the fungus grows as a mold producing infectious conidia. When these conidia enter a warm-blooded host through wounds or inhalation, they convert to a yeast form that causes tissue infection. This dimorphic nature allows the organism to survive both in the environment and within mammalian hosts. Dogs typically become infected through traumatic implantation of fungal elements into the skin during outdoor activities, hunting, or digging in contaminated soil.

Sporotrichosis manifests in dogs primarily as a cutaneous or lymphocutaneous infection, presenting as nodular skin lesions that may ulcerate and drain. The classic lymphocutaneous form involves a primary lesion at the inoculation site followed by development of secondary nodules along the draining lymphatic vessels, creating a characteristic ascending pattern. Less commonly, dogs may develop fixed cutaneous disease limited to a single site, or disseminated disease involving multiple organ systems. The disseminated form is rare in dogs but carries a more guarded prognosis and occurs more frequently in animals with compromised immune function.

Sporotrichosis is treatable in most cases with appropriate antifungal medication, though treatment duration is typically prolonged, lasting several months to ensure complete elimination of the organism. Itraconazole has become the treatment of choice for canine sporotrichosis due to its efficacy and tolerability. Prognosis for cutaneous and lymphocutaneous forms is generally good with appropriate treatment, though owner compliance with extended medication courses is essential for cure. Veterinary guidance is critical for accurate diagnosis, appropriate treatment selection, and monitoring for potential zoonotic transmission to humans. The zoonotic nature of sporotrichosis, particularly with Sporothrix brasiliensis, makes this condition of significant public health importance.

Sporotrichosis is caused by infection with fungi belonging to the Sporothrix schenckii species complex. Several species within this complex can cause disease, with Sporothrix schenckii being the historically recognized pathogen worldwide and Sporothrix brasiliensis emerging as a significant cause of disease in South America, particularly Brazil. Other species including Sporothrix globosa and Sporothrix luriei have also been identified as occasional pathogens. Understanding the specific causative species is increasingly important as they may differ in virulence, zoonotic potential, and antifungal susceptibility.

The primary route of infection in dogs is traumatic implantation of fungal elements into the skin. Sporothrix organisms live saprophytically in soil and decaying organic matter, particularly associated with plants, thorns, hay, and sphagnum moss. Dogs become infected when contaminated material penetrates the skin through wounds, scratches, or punctures. Hunting dogs that work in brushy areas are at increased risk due to frequent minor skin trauma from vegetation. Dogs that dig in soil or gardens may introduce fungal spores through small wounds on their paws or muzzle. Any outdoor activity that combines soil exposure with potential skin breaks creates opportunity for infection.

Environmental factors strongly influence the geographic distribution and seasonality of sporotrichosis. The fungus thrives in warm, humid environments with abundant organic matter. Tropical and subtropical regions including Central and South America, Southeast Asia, and parts of Africa report the highest incidence. In the United States, sporotrichosis occurs most frequently in river valleys and coastal areas with moderate temperatures and high humidity. Seasonal patterns may be observed, with increased cases following rainy periods when fungal growth is promoted. Climate change may be expanding the geographic range of Sporothrix species into previously unaffected areas.

Sporothrix brasiliensis has emerged as a particularly concerning pathogen due to its high zoonotic potential and efficient transmission from cats to humans and dogs. Unlike classic Sporothrix schenckii infection from environmental exposure, Sporothrix brasiliensis can spread directly between animals and from animals to humans. In endemic areas of Brazil, large outbreaks have occurred linked to infected cats serving as reservoirs and transmitters. Dogs living in households with infected cats or dogs that fight with stray cats face risk of acquiring this species through bites or scratches. This animal-to-animal transmission pathway represents a significant epidemiological difference from traditional environmental sporotrichosis.

Once fungal elements enter the tissue, they convert from the environmental mold form to the pathogenic yeast form. The yeast cells are able to survive within macrophages and other immune cells, allowing them to evade host defenses. The organism spreads locally through the subcutaneous tissues and may track along lymphatic vessels toward regional lymph nodes, creating the characteristic lymphocutaneous pattern. In most immunocompetent dogs, the infection remains localized to skin and lymphatic structures. However, in dogs with impaired immune function due to concurrent disease, immunosuppressive medications, or other factors, the organism may disseminate hematogenously to involve bones, joints, lungs, and other internal organs.

The clinical presentation of sporotrichosis in dogs varies depending on the form of disease and the host's immune response. Recognizing the characteristic patterns of cutaneous and lymphocutaneous sporotrichosis helps prompt appropriate diagnostic investigation and treatment initiation. Early signs may be subtle and easily mistaken for other skin conditions, bacterial infections, or minor wounds that fail to heal.

The lymphocutaneous form is the most common presentation of sporotrichosis in dogs and follows a characteristic pattern. Initial infection typically appears as a small papule or nodule at the site of fungal inoculation, often on the muzzle, limbs, or feet where contact with contaminated material is most likely. This primary lesion may enlarge and eventually ulcerate, draining serosanguineous to purulent material. Over the following weeks to months, secondary nodules develop along the lymphatic vessels draining the primary site, creating a distinctive linear or ascending pattern. These secondary lesions may also ulcerate and drain. The affected lymph nodes themselves may become enlarged.

Behavioral changes in dogs with sporotrichosis are often minimal in the early stages since the infection typically remains localized and systemic illness is absent. Dogs may lick or scratch at affected areas due to local irritation or mild discomfort. If lesions occur on the feet, some dogs may exhibit mild lameness or reluctance to walk on rough surfaces. Appetite and energy levels typically remain normal unless the disease has disseminated or secondary bacterial infection has developed. Dogs with facial lesions may show some head shyness or reluctance to have the affected area touched.

Physical examination findings in cutaneous sporotrichosis include firm nodules within the skin and subcutaneous tissues that may be freely movable or attached to underlying structures. Surface ulceration is common, and lesions often have a crusty or scabbed appearance. The tissue surrounding lesions may appear minimally inflamed or may show more extensive swelling and redness. Examination of the regional lymphatic distribution reveals the characteristic chain of nodules extending from the primary site toward the draining lymph nodes. These secondary lesions vary in size and stage of development, with some appearing as small papules while others have progressed to ulcerative lesions.

The progression of untreated sporotrichosis is typically slow compared to some other infectious diseases, reflecting the chronic nature of this fungal infection. New lesions may continue to develop over weeks to months if treatment is not initiated. Existing lesions may cycle between apparent improvement and worsening as the host immune system and fungal infection interact. The fixed cutaneous form, where infection remains limited to a single site without lymphatic spread, may appear as a chronic non-healing wound or mass that fails to respond to routine wound care or empirical antibiotics. This persistence despite standard treatment should prompt investigation for fungal or other atypical infections.

Disseminated sporotrichosis, while rare in dogs, produces more severe systemic signs warranting urgent attention. Dogs with disseminated disease may develop fever, lethargy, decreased appetite, and weight loss. Respiratory involvement causes coughing, increased respiratory rate, or labored breathing. Bone and joint involvement produces lameness, joint swelling, and pain. Multiple skin lesions appearing simultaneously across different body regions suggest hematogenous spread rather than lymphatic extension. Any signs of systemic illness in a dog with known or suspected sporotrichosis should prompt immediate veterinary evaluation for possible disseminated disease. Similarly, sporotrichosis should be considered in dogs presenting with chronic multifocal skin disease, unexplained osteoarticular signs, or respiratory disease in endemic areas.

Diagnosing sporotrichosis requires a combination of clinical suspicion, appropriate sample collection, and laboratory confirmation. The characteristic lymphocutaneous pattern provides a strong clinical clue, but definitive diagnosis requires identification of the causative organism. Veterinarians should consider sporotrichosis in any dog presenting with chronic nodular skin lesions, particularly those showing the typical linear spread along lymphatic drainage, and especially in endemic geographic regions.

The initial veterinary examination focuses on characterizing the distribution and nature of skin lesions. The veterinarian will note the location of the primary lesion and map any secondary nodules along lymphatic pathways. Physical examination includes palpation of regional lymph nodes for enlargement. A detailed history explores potential exposure sources including outdoor activities, hunting, contact with soil or plant material, and any known exposure to infected animals. Geographic travel history is particularly relevant given the regional nature of sporotrichosis. The veterinarian will also assess for signs of disseminated disease including respiratory abnormalities, joint swelling, or evidence of systemic illness.

Diagnostic sample collection for sporotrichosis may include cytology, biopsy, and culture. Fine needle aspirates or impression smears from draining lesions may reveal the yeast form of Sporothrix, though organisms can be difficult to find cytologically in dogs. The yeast cells are small and oval to cigar-shaped, but their sparse numbers in canine lesions make cytologic diagnosis unreliable. Tissue biopsy provides better diagnostic material and allows histopathologic examination. Special stains such as periodic acid-Schiff and Gomori methenamine silver help visualize fungal organisms within tissue. Histopathology typically shows pyogranulomatous inflammation, though organisms may still be difficult to detect.

Fungal culture remains the gold standard for definitive diagnosis of sporotrichosis. Samples from tissue biopsy, lesion exudate, or aspirated material are submitted to a laboratory with mycology capabilities. Sporothrix species grow on standard fungal media at room temperature as a mold and at body temperature as a yeast, demonstrating the characteristic dimorphism. Culture growth typically requires two to four weeks. Definitive species identification may require molecular testing, which has become increasingly important given the different clinical and zoonotic characteristics of various Sporothrix species. Serologic testing for sporotrichosis is available but is less commonly used in veterinary diagnosis than culture.

Differential diagnosis for nodular skin lesions with lymphatic spread includes other fungal infections such as blastomycosis and cryptococcosis, atypical mycobacterial infections, bacterial infections including nocardiosis, and neoplastic conditions. The geographic location, clinical presentation, and laboratory findings help differentiate among these possibilities. Importantly, bacterial culture and cytology showing pyogranulomatous inflammation without bacteria should prompt consideration of fungal infection. Dogs that fail to respond to empirical antibiotic therapy for presumed bacterial skin infection warrant further diagnostic investigation including fungal culture. Once sporotrichosis is confirmed, baseline bloodwork and thoracic radiographs may be recommended to assess for disseminated disease, particularly in dogs showing any systemic signs.

Treatment of sporotrichosis in dogs primarily relies on systemic antifungal medication administered for an extended duration. The goal is complete elimination of the organism to prevent relapse and ongoing transmission risk. Treatment protocols have been refined over the years, with itraconazole emerging as the preferred agent for most cases. Treatment decisions consider the form and extent of disease, the dog's overall health, potential drug interactions, and owner factors including compliance capability and financial considerations.

Itraconazole is considered the first-line treatment for canine sporotrichosis due to its efficacy, oral bioavailability, and generally favorable side effect profile. Standard dosing is typically 5 to 10 milligrams per kilogram body weight given once or twice daily with food to enhance absorption. Treatment duration is prolonged, typically continuing for a minimum of two to four weeks beyond complete clinical resolution of all lesions. Total treatment duration often extends four to six months or longer. Premature discontinuation is a common cause of treatment failure and relapse, making owner education about the importance of completing the full course absolutely essential.

Potassium iodide was historically used for treating sporotrichosis and remains an option, particularly when cost is a significant constraint. This medication is administered orally as a saturated solution and is often effective for cutaneous disease. However, dogs tolerate potassium iodide less well than itraconazole, with common side effects including gastrointestinal upset, excessive salivation, and skin reactions. The unpleasant taste requires creative administration strategies. Potassium iodide may be considered as an alternative or adjunctive therapy but has largely been supplanted by itraconazole for most patients.

Severe or disseminated sporotrichosis may require more aggressive treatment approaches. Amphotericin B, administered intravenously, may be used for initial treatment of life-threatening disseminated disease, followed by long-term oral therapy with itraconazole. Terbinafine has shown activity against Sporothrix species and may be used alone or in combination with itraconazole for difficult cases. Combination antifungal therapy is sometimes employed for refractory infections. Treatment of disseminated disease carries a more guarded prognosis and requires prolonged therapy with careful monitoring for treatment response and drug toxicity.

Supportive care complements antifungal therapy and promotes healing of skin lesions. Wound care including gentle cleaning of ulcerated lesions helps prevent secondary bacterial infection. If bacterial superinfection is present, appropriate antibiotics are prescribed based on culture and sensitivity results. Elizabethan collars may be necessary to prevent self-trauma to accessible lesions. Nutritional support ensures adequate protein and calorie intake for tissue healing. Pain management is rarely needed for uncomplicated cutaneous disease but may be indicated if lesions are particularly extensive or if bone involvement is present.

Monitoring during treatment involves regular veterinary examinations to assess clinical response and screen for drug-related adverse effects. Itraconazole can cause hepatotoxicity, so baseline liver values should be obtained before starting treatment and monitored periodically during therapy, typically every four to six weeks. Clinical response is evaluated by measuring lesion size, assessing new lesion development, and monitoring for lymph node reduction. Most dogs show visible improvement within the first month of treatment, though complete resolution takes considerably longer. Treatment is continued until all clinical signs have resolved and then extended for an additional two to four weeks minimum. Owners must understand that visible healing does not indicate the organism has been eliminated and that completing the full treatment course is essential for cure.

Recovery from sporotrichosis follows a predictable trajectory in most dogs when appropriate antifungal treatment is administered consistently. The timeline for improvement varies based on disease extent at diagnosis and individual response to medication, but owners can generally expect gradual clinical improvement over weeks to months. Understanding the expected recovery pattern helps owners maintain treatment compliance through the prolonged therapy period.

The initial weeks of treatment typically show modest but encouraging changes. Active ulcerative lesions often begin to dry and develop healthy granulation tissue within the first two to three weeks. New lesion development should cease once effective treatment is established. Existing nodules may initially remain unchanged or even appear slightly larger due to the inflammatory response to dying organisms before gradually softening and shrinking. Owners should not expect dramatic improvement immediately but rather look for stability and early signs of healing. Any continued development of new lesions beyond the first few weeks of treatment suggests treatment failure and requires veterinary reassessment.

Post-treatment care focuses on completing the medication course and monitoring for relapse. Even after visible lesions have resolved, treatment must continue for the prescribed duration to eliminate residual organisms. Following treatment completion, dogs should be monitored for any recurrence of skin lesions over the subsequent months. Veterinary recheck examinations are typically recommended at the end of treatment and again two to three months later to confirm sustained resolution. Dogs that experience relapse require retreatment, often with a longer duration or alternative antifungal agent.

The prognosis for cutaneous and lymphocutaneous sporotrichosis in dogs is good with appropriate treatment. Most dogs achieve complete cure with properly administered antifungal therapy. Scarring may persist at sites of previous ulcerative lesions but is typically cosmetic and does not cause functional impairment. Dogs with disseminated disease have a more guarded prognosis, and some may not respond to treatment despite aggressive therapy. Factors associated with poorer outcomes include delayed diagnosis with extensive disease burden, underlying immunosuppression, and poor owner compliance with treatment protocols.

Long-term outlook for recovered dogs is excellent, with most returning to completely normal lives. Reinfection is possible if the dog continues to be exposed to Sporothrix in the environment, though prior infection may confer some degree of immunity. Owners should remain aware of the zoonotic potential of sporotrichosis and practice appropriate hygiene during treatment and recovery. Household contacts should be monitored for any skin lesions that might indicate human infection, and medical attention should be sought promptly if suspected. Once treatment is completed and the dog is confirmed cured, no special ongoing precautions are typically necessary.

Preventing sporotrichosis involves reducing exposure to the fungal organism in the environment and minimizing transmission from infected animals. While complete prevention may not be achievable for dogs with significant outdoor exposure in endemic areas, understanding risk factors and implementing protective measures can reduce infection likelihood. Prevention takes on added importance given the zoonotic nature of this disease and its potential for transmission to human family members.

The primary prevention strategy focuses on avoiding environmental exposure sources. Dogs should be prevented from digging in soil and leaf litter in endemic areas where possible. Gardens, compost piles, and areas with decaying plant material represent potential fungal reservoirs. Rose gardens and areas with thorny vegetation pose particular risk due to the historical association with rose thorns. While restricting all outdoor activity is neither practical nor desirable for most dogs, awareness of higher-risk environments allows owners to minimize unnecessary exposure. Promptly cleaning and treating any wounds sustained during outdoor activities may help prevent establishment of infection.

Responsible breeding practices play no direct role in sporotrichosis prevention since the disease is not hereditary. However, breeders should ensure that breeding dogs are healthy and free from active infection. Puppies born to infected mothers could potentially acquire infection through environmental contamination rather than vertical transmission. In areas endemic for Sporothrix brasiliensis, particular attention should be paid to avoiding infected cats, which serve as highly efficient transmission sources. Breeding kennels should not be located in proximity to feral cat colonies in endemic regions.

Nutritional excellence supports overall immune function, which helps determine outcome if exposure occurs. Dogs fed balanced, complete diets appropriate for their life stage maintain optimal immune competence. While no specific dietary intervention prevents sporotrichosis, avoiding malnutrition and maintaining healthy body condition are generally protective against infectious diseases. Dogs with conditions causing immunosuppression may be at increased risk for developing severe or disseminated disease if exposed, highlighting the importance of managing underlying health conditions.

Regular veterinary care enables early detection and treatment of sporotrichosis, improving outcomes and reducing transmission risk. Owners in endemic areas should be educated about the characteristic presentation of this disease and advised to seek prompt evaluation for unexplained skin nodules or non-healing wounds. Veterinarians familiar with regional disease patterns can provide specific prevention guidance. Early diagnosis and treatment shorten the period during which an infected dog can potentially transmit the organism to other animals or humans. The zoonotic risk makes human family member education important, with particular emphasis on avoiding direct contact with draining lesions and practicing hand hygiene after handling affected dogs during treatment.

Managing a dog with sporotrichosis during treatment requires consistent medication administration, appropriate wound care, and attention to preventing transmission to humans and other animals. The prolonged treatment duration presents challenges for owner compliance, making education about the importance of completing therapy essential. Understanding day-to-day management requirements helps owners provide optimal care while protecting themselves and others from this zoonotic infection.

Daily medication management forms the cornerstone of sporotrichosis treatment success. Itraconazole should be administered consistently at the prescribed dose, typically with food to maximize absorption. Establishing a routine medication schedule helps ensure doses are not missed. Liquid formulations may be easier to administer for some dogs and allow more precise dosing for smaller patients. If a dose is missed, it should be given as soon as remembered unless it is close to the next scheduled dose. Owners should maintain a medication log to track administration and note any observed side effects including decreased appetite, vomiting, or behavioral changes that might indicate medication intolerance.

Wound care and hygiene practices protect both the dog and human handlers. Draining lesions should be gently cleaned with mild antiseptic solutions as directed by the veterinarian. Bandaging may be appropriate for some lesions to contain drainage and prevent environmental contamination. All wound care should be performed wearing disposable gloves, which should be discarded immediately after use. Hands should be washed thoroughly with soap and water after any contact with the dog or its lesions, even when gloves were worn. Contaminated bandages and cleaning materials should be disposed of in sealed bags.

Home environment management during treatment focuses on reducing contamination and preventing spread to other animals. Bedding should be washed frequently in hot water. Areas where the dog rests should be cleaned regularly. If there are other pets in the household, minimizing direct contact with the infected dog is advisable until treatment is well established and lesions are healing. This is particularly important in households with cats, which are highly susceptible to Sporothrix brasiliensis. Dogs should be restricted from interacting with unfamiliar animals during treatment to prevent potential transmission.

Quality of life for dogs undergoing sporotrichosis treatment is typically good since the infection usually does not cause systemic illness in the cutaneous and lymphocutaneous forms. Dogs can continue normal activities with appropriate precautions. Exercise and mental stimulation should be maintained, though activities that risk wound contamination or new skin trauma may need modification. Most dogs remain comfortable throughout treatment, and their appetite and energy should be normal. Any decline in wellbeing during treatment warrants veterinary evaluation to assess for drug side effects or disease complications.

Caregiver considerations extend to all family members, particularly those with potential immunocompromise. Elderly individuals, young children, pregnant women, and anyone with immune system disorders face increased risk if exposed to Sporothrix. These individuals should avoid direct contact with infected dogs until treatment is complete and all lesions have healed. All family members should be educated about the signs of sporotrichosis in humans, which presents similarly to the canine form with nodular skin lesions often in a lymphocutaneous pattern. Any suspicious lesions in household members should prompt immediate medical evaluation with disclosure of the dog's diagnosis. The treating physician should be informed of the specific Sporothrix species if known, as this affects treatment decisions in humans.

Sporotrichosis does not demonstrate true breed predisposition as susceptibility is determined by exposure opportunity rather than genetic factors. Any dog exposed to Sporothrix organisms through environmental contact or transmission from infected animals can develop infection regardless of breed. However, certain breeds appear overrepresented in case reports due to lifestyle factors and activities that increase exposure risk. Understanding these risk patterns helps focus prevention education and clinical vigilance.

Breeds commonly affected by sporotrichosis include hunting dogs of various breeds, particularly those working in brush, woodland, and wetland environments where soil and decaying vegetation exposure is high. Hounds, retrievers, pointers, and other sporting breeds frequently engage in activities that predispose to this infection. Terriers, with their instinct for digging and pursuing quarry into burrows, may face elevated risk through soil exposure. Large breed dogs used for outdoor work and protection may also be overrepresented simply due to their increased environmental exposure. However, small breed dogs, mixed breeds, and companion animals of any type can develop sporotrichosis if exposed.

Geographic location is far more predictive of sporotrichosis risk than breed. Dogs living in tropical and subtropical regions with warm, humid climates face the highest environmental exposure. In the United States, sporotrichosis is most common in river valleys and coastal areas. Brazil and other South American countries report high rates, particularly of Sporothrix brasiliensis. Dogs in urban areas of endemic regions may be exposed through contact with infected stray or feral cats rather than through traditional environmental routes. Age does not appear to be a significant risk factor, though young adult dogs may be overrepresented due to higher activity levels.

Screening for sporotrichosis in clinically normal dogs is not recommended. Prevention efforts focus on exposure reduction and owner education rather than routine testing. Breeders in endemic areas should ensure breeding stock is healthy and free from active skin disease. Dogs being transported from endemic areas should be examined for suspicious skin lesions before movement. Veterinarians practicing in endemic regions should maintain high clinical suspicion for sporotrichosis when evaluating chronic nodular skin disease. Education of owners about the characteristic presentation of this infection enables prompt treatment seeking and improves outcomes.

Sporotrichosis shares clinical and histopathologic features with several other infectious and neoplastic conditions affecting the skin and subcutaneous tissues. Understanding these relationships supports accurate differential diagnosis and ensures appropriate treatment. Additionally, sporotrichosis may occur alongside other conditions or lead to secondary complications requiring concurrent management.

Conditions that commonly occur with sporotrichosis include secondary bacterial infections and regional lymphadenopathy. Ulcerated skin lesions provide opportunity for bacterial colonization and superinfection, which may require antibiotic therapy in addition to antifungal treatment. Culture of lesion exudate helps identify bacterial pathogens and guide antibiotic selection. The lymphatic involvement characteristic of sporotrichosis causes enlargement of regional lymph nodes, which may be confused with neoplastic lymphadenopathy. In areas endemic for both sporotrichosis and leishmaniasis, dual infection has been reported and should be considered in dogs with compatible clinical signs.

Several conditions produce clinical presentations similar to sporotrichosis and must be differentiated for appropriate treatment. Other subcutaneous fungal infections including blastomycosis, histoplasmosis, and cryptococcosis can cause nodular skin lesions, though they less commonly produce the typical lymphocutaneous spread pattern. Atypical mycobacterial infections, particularly those caused by rapidly growing mycobacteria, create nodules and draining tracts that may closely resemble sporotrichosis. Bacterial infections including nocardiosis and actinomycosis enter the differential diagnosis. Neoplastic conditions, particularly mast cell tumors and other skin cancers, may present as nodular masses requiring biopsy for differentiation. Foreign body reactions with secondary granuloma formation can also mimic sporotrichosis.

Potential complications of sporotrichosis include disease dissemination and treatment-related adverse effects. While disseminated disease is uncommon in dogs, spread to bones, joints, and internal organs carries a significantly worse prognosis and requires more aggressive treatment. Secondary bacterial infections of skin lesions can delay healing and cause localized cellulitis. Long-term itraconazole therapy may cause hepatotoxicity, necessitating periodic monitoring of liver values. Drug interactions can occur when itraconazole is administered alongside other medications metabolized by the cytochrome P450 enzyme system. Recognition of these potential complications guides monitoring protocols and treatment adjustments.